Trinity Biotech (NASDAQ:TRIB) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report released on Sunday. The firm issued a buy rating on the stock.

Trinity Biotech Stock Performance

TRIB stock opened at $1.69 on Friday. The stock has a market capitalization of $12.88 million, a PE ratio of -0.61 and a beta of 1.24. The company has a fifty day moving average of $1.84 and a 200-day moving average of $2.15. Trinity Biotech has a one year low of $1.49 and a one year high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) earnings per share (EPS) for the quarter. The company had revenue of $13.43 million for the quarter.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.